2840-71-3

Usage

Uses

Used in Sleep Regulation:
5-methoxy-4,4-dimethyl-5-oxopentanoic acid is used as a sleep-regulating hormone for its role in maintaining the sleep-wake cycle. It helps in treating sleep disorders and jet lag by adjusting the circadian rhythm.
Used in Dietary Supplements:
5-methoxy-4,4-dimethyl-5-oxopentanoic acid is used as a dietary supplement for its sleep-inducing effects. It is widely consumed to improve sleep quality and promote relaxation.
Used in Anti-inflammatory Applications:
In the pharmaceutical industry, 5-methoxy-4,4-dimethyl-5-oxopentanoic acid is used as an anti-inflammatory agent for its potential role in reducing inflammation. It may help in managing conditions associated with chronic inflammation.
Used in Immune Function Improvement:
5-methoxy-4,4-dimethyl-5-oxopentanoic acid is used as an immune function enhancer for its potential role in improving immune response. It may contribute to a stronger immune system and overall well-being.
Used in Research:
In the scientific research field, 5-methoxy-4,4-dimethyl-5-oxopentanoic acid is used as a subject of study for its potential therapeutic applications. Researchers are exploring its effects on various conditions related to circadian rhythm disturbances and its antioxidant properties.

Upstream product

• 13051-32-6 dimethyl 2,2-dimethylglutarate 
• 67-56-1 methanol 
• 2938-48-9 3,3-dimethyl glutaric acid anhydride 
• 31469-15-5 1-methoxy-2-methyl-1-trimethylsiloxy-1-propene 
• 814-68-6 acryloyl chloride 
• 681-57-2 2,2-dimethylglutaric acid 

Downstream Products

• 957121-16-3 methyl 5-(3,5-difluorophenyl)-2,2-dimethyl-5-oxopentanoate 
• 957121-12-9 (6S)-6-(3,5-difluorophenyl)-3,3-dimethylpiperidin-2-one 
• 957121-18-5 methyl (5S)-5-{[(S)-tert-butylsulfinyl]amino}-5-(3,5-difluorophenyl)-2,2-dimethylpentanoate 
• 1211383-10-6 ethyl (5S)-5-{[(S)-tert-butylsulfinyl]amino}-5-(3,5-difluorophenyl)-2,2-dimethylpentanoate 
• 1363365-31-4 methyl 2,2-dimethyl-4-(3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl)butanoate 

Relevant academic research and scientific papers

Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs

Interleukin-1 receptor associated kinase 4 (IRAK4) is a promising therapeutic target for diffuse large B-cell lymphoma driven by MYD88 L265P mutant, acting both as a kinase and a scaffolding protein for downstream signaling molecules. While previous efforts to modulate IRAK4 activity with kinase inhibitors alone displayed moderate efficacy, protein degradation may offer a solution to blocking both IRAK4 kinase activity and scaffolding capabilities. To this end, the potent IRAK4 degrader 9 was discovered, and it effectively inhibited the activation of downstream NF-κB signaling and outperformed the parent compound 1. In addition, compound 9 displayed a substantial advantage in reduction of the viability of OCI-LY10 and TMD8 cells over the parent compound 1. These results underline the potential that eliminating both the kinase and scaffolding functions of IRAK4 may result in superior and broader efficacy than inhibiting the kinase activity alone.

TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF

A compound represented by Formula [I]: or pharmaceutically acceptable salt thereof, wherein each symbol is as defined in the description.

Synthesis, characterization, and DGAT1 inhibition of new 5-piperazinethiazole and 5-piperidinethiazole analogs

In this study, a novel series of 5-piperazinethiazole 2,2-dimethylbutanoic acid and 5-piperidinethiazole 2,2-dimethylbutanoic acid derivatives have been synthesized. Structures of the newly synthesized compounds have been elucidated using 1H-NMR, 13C-NMR, high-resolution mass spectroscopy, and high-performance liquid chromatographic analysis. The synthesized derivatives have been evaluated in vitro for their ability to inhibit the enzyme diacylglycerol acyltransferase 1 responsible for triglyceride biosynthesis.

HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS

The present invention relates to heterocyclic compounds of formula 1, in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, carboxylic acid isosteres and N-oxides. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

Novel CGRP receptor antagonists from central amide replacements causing a reversal of preferred chirality

A previously utilized quinoline-for-N-phenylamide replacement strategy was employed against a central amide in a novel class of CGRP receptor antagonists. A unique and unexpected substitution pattern was ultimately required to maintain reasonable affinity

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

MONOCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of the formula (I) : (wherein variables A1, A2, A3, A4, A5, A6, A7, A8, G1, G2, G3, G4, J, Q, Ea, Eb, Ec, R6, R7, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Substituted monocyclic CGRP receptor antagonists

Compounds of formula I: (wherein variables A1, A2, A3, A4, m, n, J, Q, R4, Ea, Eb, Ec, R6, R7, Re, Rf, RPG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists

Lactam and cyclic urea derivatives and their pharmaceutically acceptable salts are disclosed. The synthesis of these compounds and their use as alpha 1aadrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are typically selective in their ability to relax smooth muscle tissue enriched in the alpha 1areceptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved.

Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816

Thiopyrano[2,3,4-c,d]indoles are a new class of 5-lipoxygenase (5-LO) inhibitors. SAR studies have demonstrated that the thiopyran ring, the 5- phenylpyridine substituent, and an acidic functional group on a four-carbon C-2 side chain are all required for optimal inhibitor potency. In contrast, the indolic nitrogen may be substituted with a variety of lipophilic groups. As a result of the SAR investigation, 44 (L-691,816; 5-[3-[1-(4- chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H- thiopyrano[2,3,4-c,d]indol-2-yl]-2,2-dimethylpropyl]-1H-tetrazole) has been identified as a potent inhibitor of the 5-LO reaction both in vitro and in a range of in vivo models. Compound 44 inhibits 5-HPETE production by both rat and human 5-LO and LTB4 synthesis in human PMN leukocytes (IC50s 16, 75, and 10 nM, respectively). The mechanism of inhibition of 5-LO activity by compound 44 appears to involve the formation of a reversible deadend complex with the enzyme and does not involve reduction of the nonheme iron of 5-LO. Compound 44 is highly selective for 5-LO when compared to the inhibition of human FLAP, porcine 12-LO, and also ram seminal vesicle cyclooxygenase. In addition, 44 is orally active in a rat pleurisy model (inhibition of LTB4, ED50 = 1.9 mg/kg; 8 h pretreatment) as well as in the hyperreactive rat model of antigen-induced dyspnea (ED50 = 0.1 mg/kg; 2-h pretreatment). Excellent functional activity was also observed in both the conscious allergic monkey and sheep models of asthma. In the latter case, the functional activity observed correlated with the inhibition of urinary LTE4 excretion.